SynthesisCardiovascular research2026
Impact of amino acid supplementation on cardiovascular and chronic kidney diseases: a systematic review.
Synthesis in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Amino acid homeostasis in the kidney: Physiological roles and pathological dysregulation.Physiological reports · 2026Review
- The Janus face of L-arginine supplementation in cardiovascular health and aging exploration of underlying mechanisms.Frontiers in aging · 2026Review
- A novel continuous-progression CKM model combined with multi-omics data integration identifies lipid metabolic drivers of disease progression.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cardiovascular diseases (CVD) remain the leading cause of mortality worldwide, with chronic kidney disease (CKD) constituting a significant risk factor. Despite the crucial role of amino acids as fundamental dietary components, their impact on the comorbidities of CKD and CVD has been insufficiently studied and warrants greater research attention. Therefore, this systematic review provides a comprehensive overview of the current knowledge regarding the effects of amino acid supplementation on the comorbidities associated with CVD and CKD, as the basis for novel prevention and treatment options. The databases 'PubMed' and 'Web of Science' were used to perform a literature search on the effects of amino acid supplementation on the comorbidities associated with CVD and CKD. Data synthesis was conducted based on 60 publications, comprising 13 clinical, 43 in vivo and four in vitro studies. The risk of bias was assessed using three appropriate tools. Studies were classified based on preventive or harmful effects. Altogether, 43 publications reported preventive, and 18 described adverse effects, of which three described both preventive and adverse effects of different amino acids. Only two publications showed no effects caused by amino acids. Arginine and methionine were attributed to the highest number of preventive and adverse effects, respectively. However, a limitation of most publications is the pending translation to humans. Overall, these findings suggest that amino acid supplementation as a potentially valuable addition to treatment options for CVD and CKD patients, although further clinical studies are needed for validation of these findings. This systematic review was funded by the German Research Foundation (DFG, SFB/TRR219) and was registered in the PROSPERO database (CRD42023493924).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.